

OFFICIAL

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent and
Trademark Office on November 21, 2003.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.116

Examining Group 1642

Patent Application

Docket No. USF-T136

Serial No. 09/444,711

**RECEIVED
CENTRAL FAX CENTER****NOV 21 2003****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner : Alana M. Harris
Art Unit : 1642
Applicants : Timothy J. Yeatman, Rosalyn B. Irby
Serial No. : 09/444,711
Filed : November 24, 1999
Confirm. No. : 9003
For : Mutated SRC Oncogene Composition and Methods

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.116

In response to the Office Action dated September 24, 2003, please amend the above-
identified application as follows:

J:\USFT136\Amend-Resp\Resp AF.doc/DNB/mv

OK
to enter
amh
2/17/2004

2

Docket No. USF-T136

Serial No. 09/444,711

In the Claims

Claims 1-112 (Cancelled)

¹
Claim ~~113~~ (Previously added): An isolated polynucleotide encoding a ^{truncated} mutant c-Src polypeptide, wherein said ^{truncated} mutant c-Src polypeptide ^{consists of} comprises SEQ ID NO:4.

²
Claim ~~114~~ (Previously added): The isolated polynucleotide of claim ~~113~~, wherein said polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO:3.

~~Claim 115 (Previously added): The isolated polynucleotide of claim 113, wherein said mutant c-Src polypeptide consists of SEQ ID NO:4.~~

³
Claim ~~116~~ (Previously added): An isolated polynucleotide encoding a ^{truncated} mutant c-Src polypeptide, wherein said polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO:3, or a full-length complement thereof.

⁴
Claim ~~117~~ (Previously added): An isolated transgenic cell having incorporated therein a recombinant construct, wherein said recombinant construct comprises:

(a) a polynucleotide encoding a ^{truncated} mutant c-Src polypeptide, wherein said ^{truncated} mutant c-Src polypeptide ^{consists of} comprises SEQ ID NO:4; and

(b) at least one regulatory element operably linked to said polynucleotide.

⁵
Claim ~~118~~ (Previously added): The isolated transgenic cell of claim ~~117~~, wherein said polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO:3.

~~Claim 119 (Previously added): The isolated transgenic cell of claim 117, wherein said mutant c-Src polypeptide consists of SEQ ID NO:4.~~

JAUSFT136Amend-Resp\Resp AF.doc/DNB/mv

3

Docket No. USF-T136

Serial No. 09/444,711

Claim ⁶120 (Previously added): The isolated transgenic cell of claim ⁴117, wherein said recombinant construct is an expression vector.

Claim ⁷121 (Previously added): An isolated transgenic cell having incorporated therein a recombinant construct, wherein said recombinant construct comprises:

- (a) a polynucleotide encoding a ^{truncated}mutant c-Src polypeptide, wherein said polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO:3, or a full-length complement thereof; and
- (b) at least one regulatory element operably linked to said polynucleotide.

Claim ⁸122 (Previously added): The transgenic cell of claim ⁶121, wherein said recombinant construct is an expression vector.

Claim ⁹123 (Previously added): An isolated host cell transfected with a polynucleotide comprising a nucleotide sequence encoding a ^{truncated}mutant c-Src polypeptide, wherein said ^{truncated}mutant c-Src polypeptide ^{consists of}comprises SEQ ID NO:4.

Claim ¹⁰124 (Previously added): The isolated host cell of claim ¹⁰123, wherein said nucleotide sequence comprises nucleotides 1 to 1593 of SEQ ID NO:3.

~~Claim 125 (Previously added): The isolated host cell of claim 123, wherein said mutant c-Src polypeptide consists of SEQ ID NO:4.~~

Claim ¹¹126 (Previously added): The isolated host cell of claim ¹⁰123, wherein said polynucleotide further comprises a promoter operably linked to said nucleotide sequence encoding said ^{truncated}mutant c-Src polypeptide.

Claim ¹²127 (Previously added): An isolated host cell transfected with a polynucleotide comprising a nucleotide sequence encoding a ^{truncated}mutant c-Src polypeptide, wherein said nucleotide sequence comprises nucleotides 1 to 1593 of SEQ ID NO:3, or a full-length complement thereof.

J:\USFT136\Amend-Resp\Resp AF.doc/DNB/mv

4

Docket No. USF-T136
Serial No. 09/444,711

¹³
Claim ¹²128 (Previously added): The isolated host cell of claim 127, wherein said polynucleotide further comprises a promoter operably linked to said nucleotide sequence encoding said ^{truncated} mutant c-Src polypeptide.

Claims 129-130 (Cancelled)

¹⁴
Claim 131 (Currently amended): ~~The oligonucleotide of claim 129, wherein said mutant c-Src polypeptide consists of SEQ ID NO:4~~ An oligonucleotide capable of recognizing and distinguishing a mutant c-Src gene from a wild-type c-Src gene, wherein said mutant c-Src gene comprises a polynucleotide encoding a ^{truncated} mutant c-Src polypeptide, and wherein said ^{truncated} mutant c-Src polypeptide consists of SEQ ID NO:4.

Claims 132-138 (Cancelled)

¹⁵
Claim ¹⁴139 (Currently amended): ~~The diagnostic kit of claim 137, wherein said mutant c-Src polypeptide consists of SEQ ID NO:4~~ A diagnostic kit comprising an oligonucleotide capable of recognizing and distinguishing a mutant c-Src gene from a wild-type c-Src gene, wherein said mutant c-Src gene comprises a polynucleotide encoding a ^{truncated} mutant c-Src polypeptide, and wherein said ^{truncated} mutant c-Src polypeptide consists of SEQ ID NO:4.

Claims 140-146 (Cancelled)

¹⁶
Claim ^{truncated}147 (Previously added): A method for producing a ^{truncated} mutant c-Src protein, said method comprising:
(a) culturing an isolated transgenic cell under conditions suitable for expression of the ^{truncated} mutant c-Src protein, wherein the isolated transgenic cell has incorporated therein an expression vector comprising a polynucleotide encoding the ^{truncated} mutant c-Src protein and at least one regulatory element

J:\USF\T136\Amend-Resp\Resp AF.doc/DNB/mv

5

Docket No. USF-T136
Serial No. 09/444,711

operably linked to said polynucleotide, wherein the ^{truncated} mutant c-Src protein ^{consists of} comprises SEQ ID NO:4;
and

(b) recovering the ^{truncated} mutant c-Src protein from the isolated transgenic cell or cell culture.

¹⁷ Claim ~~148~~ (Previously added): The method of claim ¹¹⁶ ~~147~~, wherein the polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO:3.

~~Claim 149 (Previously added): The method of claim 147, wherein the mutant c-Src protein consists of SEQ ID NO:4.~~

¹⁸ Claim ~~150~~ (Previously added): A method for producing a ^{truncated} mutant c-Src protein, said method comprising:

(a) culturing an isolated host cell under conditions suitable for expression of the ^{truncated} mutant c-Src protein, wherein the isolated host cell has been transfected with a polynucleotide comprising a nucleotide sequence encoding the ^{truncated} mutant c-Src protein, wherein the ^{truncated} mutant c-Src protein ^{consists of} comprises SEQ ID NO:4; and

(b) recovering the ^{truncated} mutant c-Src protein from the isolated transgenic cell or cell culture.

¹⁹ Claim ~~151~~ (Previously added): The method of claim ¹¹⁸ ~~150~~, wherein the polynucleotide further comprises a promoter operably linked with the nucleotide sequence encoding the ^{truncated} mutant c-Src protein.

²⁰ Claim ~~152~~ (Previously added): The method of claim ¹¹⁸ ~~150~~, wherein the polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO:3.

~~Claim 153 (Previously added): The method of claim 150, wherein the mutant c-Src protein consists of SEQ ID NO:4.~~